I don't see the valuation as being too high, based on the number trials underway and the good penetration into the US market. So looking at it from the potential I see it as being priced alright, and should go higher (I hope). Also I guess one shouldn't forget they have at present a healthy bank balance when compared to many other companies.
chart, page-5
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)